# A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

> **NCT07222956** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Moein Amin** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Sclerosis (MS) - Relapsing-remitting
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis (MS) Primary Progressive

## Interventions

- **DRUG:** Remibrutinib (Open Label)

## Key facts

- **NCT ID:** NCT07222956
- **Lead sponsor:** Moein Amin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-10-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222956, "A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07222956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*